Shifting from Inpatient to Outpatient Treatment of Deep Vein Thrombosis in a Tertiary Care Center: A Cost‐Minimization Analysis
- 1 March 2003
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 23 (3) , 301-309
- https://doi.org/10.1592/phco.23.3.301.32102
Abstract
Study Objective. To compare the cost of contemporary outpatient and historical inpatient management of proximal lower limb deep vein thrombosis (DVT) in adults. Design. Prospective, observational study with historical inpatient cases as controls. Setting. Ambulatory thrombosis clinic of a tertiary care teaching center in Canada. Patients. Forty‐nine inpatients with DVT from a previous study in 1996 at the same institution who would have been eligible for outpatient therapy if this option had been available, and 51 consecutive patients referred to the ambulatory thrombosis clinic for treatment of DVT between March 2000 and January 2001. Intervention. The 49 inpatients received unfractionated heparin, and the 51 outpatients received low‐molecular‐weight heparin (LMWH). Measurements and Main Results. A cost‐minimization analysis restricted to the hospital perspective was conducted. This design was justified based on the clinical equivalence of the two treatment strategies. All direct hospital costs for treating the 51 consecutive outpatients with LMWH were measured. These data were compared with the cost of treating the inpatients with unfractionated heparin. The analysis horizon was limited to 7 days, based on the duration of hospitalization and length of heparin therapy for DVT before conversion to oral warfarin. The mean cost (in Canadian dollars) per outpatient case was $248 (95% confidence interval $216–280) and was significantly different from the mean cost/inpatient case of $2826 (adjusted for the difference in fiscal years) (p<0.0005). A breakdown of the outpatient cost showed that nursing time contributed to 51% of the cost, monitoring laboratory tests 5%, drugs 2%, and other costs (diagnostic laboratory tests and medical imaging) 42%. Conclusion. Converting from inpatient to outpatient treatment of proximal DVT was associated with a significant cost savings for our institution. Accordingly, it is financially advantageous for hospitals to offer this service as it reduces direct costs and does not appear to compromise patient care.Keywords
This publication has 23 references indexed in Scilit:
- Clinical Outcome and Cost of Hospital vs Home Treatment of Proximal Deep Vein Thrombosis With a Low-Molecular-Weight HeparinArchives of internal medicine (1960), 2000
- Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosisJournal of General Internal Medicine, 2000
- The Role of Age in Cost-Benefit Analysis of ThromboprophylaxisSeminars in Thrombosis and Hemostasis, 1999
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- Low-Molecular-Weight Heparin in the Treatment of Patients with Venous ThromboembolismNew England Journal of Medicine, 1997
- Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspectiveArchives of internal medicine (1960), 1997
- Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis A feasibility and health economic study in an outpatient settingJournal of Internal Medicine, 1996
- A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein ThrombosisNew England Journal of Medicine, 1996
- Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at HomeNew England Journal of Medicine, 1996
- ANTICOAGULANT DRUGS IN THE TREATMENT OF PULMONARY EMBOLISMThe Lancet, 1960